SCHEMBL3606359

SCHEMBL3606359

CN1c2cccc(N)c2NC(=O)C1(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 3/20 0.36
KMT2A Q03164 5/20 0.35
MEN1 O00255 4/20 0.35
USP2 O75604 3/20 0.35
PDK4 Q16654 2/20 0.35
PDK1 Q15118 1/20 0.35
PDK3 Q15120 1/20 0.35
ATM Q13315 1/20 0.35
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
ALDH1A1 P00352 4/20 0.33
GAA P10253 3/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPT P10636 3/20 0.33
NSD2 O96028 1/20 0.33
APP P05067 1/20 0.33
HPGD P15428 1/20 0.33
SNCA P37840 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3606355 0.80 PDK2 (0.36) PDK2KMT2AMEN1PDK4PDK1
SCHEMBL3599452 0.73 PDK2 (0.44) PDK2KMT2AMEN1USP2PDK4
SCHEMBL3588408 0.70 CRBN (0.42) KMT2AMEN1USP2ATMKEAP1
SCHEMBL3595403 0.69 BRD4 (0.36) PDK2KMT2AMEN1USP2PDK4
SCHEMBL3585335 0.67 NR1H2 (0.40) PDK2KMT2AMEN1PDK4ALDH1A1
SCHEMBL3591085 0.67 NR1H2 (0.37) PDK2KMT2APDK4ALDH1A1GAA
SCHEMBL4409661 0.66 PDK2 (0.41) PDK2KMT2AMEN1USP2PDK4
SCHEMBL3599302 0.66 BRD4 (0.45) PDK2KMT2AMEN1USP2PDK4
SCHEMBL3593393 0.64 RXFP1 (0.36) PDK2KMT2AMEN1PDK4PDK1
SCHEMBL2034057 0.62 DPP4 (0.39) PDK2KMT2AMEN1USP2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 PDK2 3637/4885KMT2A 906/4885MEN1 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.